Tech Latest dispatch
August 2, 2026 was supposed to be the day the EU AI Act's toughest rules hit high-risk systems. Then the Digital Omnibus moved the goalposts. Here's what actually changed, and what it means for AI in drug discovery.
Everything else from the field.
The Bipartisan Commission on Biodefense added AI as the first new technology priority to the Apollo Program since 2021. The technical evidence behind that decision comes from a red-team exercise in which AI-redesigned toxin sequences slipped past the screening software that DNA synthesis companies rely on.
The 2026 Bundibugyo epidemic is now the largest Ebola outbreak ever recorded in the DRC, against a virus for which no licensed vaccine or therapy exists. It is also the first serious field test of AI-era biology's central promise — and the results are more sobering, and more interesting, than the hype allows.
The US government's July 28 policy prohibits dangerous gain-of-function research outright. But purely computational design of novel biological agents is explicitly not prohibited — it gets an interagency monitoring group instead. Here's what the policy says, why the split matters, and what it doesn't tell us.
A new peer-reviewed study cut AI-redesigned toxin genes into fragments and fed them to four commercial DNA screening tools. Two caught fragments as short as 50 nucleotides. Here's what that means ten weeks before a US screening deadline — and why the authors are still worried.
Genome sequencing published this week places the virus behind Central Africa's fastest-growing Ebola outbreak on a distinct branch of the Bundibugyo family tree — with an evolutionary signal nobody expected. Here is what that means for diagnostics built on the wrong prior, and where AI-assisted sequencing genuinely helps.
OpenAI is giving 100,000 academic researchers free frontier model access with 75+ life science skills. Anthropic's newest flagship refuses to explain mitochondria. Both companies claim to be managing the same biosecurity risk — and the gap between their answers tells you how unsettled AI-for-biology governance really is.
A multimodal benchmark of 322 expert-validated questions finds OpenAI's o3 outperforms 94% of PhD virologists on troubleshooting complex lab protocols. We unpack what changed, what it doesn't prove, and why pandemic-preparedness planners should care.
For about three years, the standard frontier-lab position on biology was defensive. Biology was the scary quadrant of the risk matrix.
